STOCK TITAN
  1. Home
  2. Sec-filings
  3. OPK
  4. [Form 4] OPKO HEALTH, INC. Insider Trading Activity

[Form 4] OPKO HEALTH, INC. Insider Trading Activity

Filing Impact
(Very High)
Filing Sentiment
(Positive)
Form Type
4

Rhea-AI Filing Summary

OPKO Health (OPK) insider Phillip Frost, M.D., who serves as CEO, Chairman and a 10% owner, reported multiple open market purchases of the company’s common stock. On 11/19/2025, he bought a total of 580,000 shares in several transactions at prices ranging from $1.28 to $1.32 per share. Following these transactions, he was reported as indirectly beneficially owning 215,546,448 shares through Frost Gamma Investments Trust, with additional holdings of 3,568,951 shares directly and 30,127,177 shares indirectly through Frost Nevada entities, while expressly disclaiming beneficial ownership beyond his pecuniary interest.

Positive

  • None.

Negative

  • None.

Insights

Insider, already a major holder, increased indirect ownership via open‑market purchases with no offsetting sales, modestly positive governance signal.

The filing shows that **Phillip Frost, M.D.**, a **Director, CEO, Chairman, and 10% owner** of **OPKO Health, Inc.**, executed multiple open-market purchases of common stock on 11/19/2025. Across several trades priced between $1.28 and $1.32 per share, the reporting person acquired a total of **580,000** shares coded "P" (purchase), all reported as **indirect** holdings through Frost Gamma Investments Trust. After these transactions, the reported indirect beneficial ownership through this structure rose to **215,546,448** shares.

In addition to these indirect holdings, the filing reports **3,568,951** shares held directly and **30,127,177** shares held indirectly through a separate structure (Frost Nevada Investments Trust). The explanatory footnotes detail complex ownership chains but also state that the reporting person **disclaims beneficial ownership** beyond any pecuniary interest, which is a standard legal position in such multi-entity arrangements. From a governance perspective, the key fact is that there were **purchases only, no dispositions**, which increases the reporting person’s economic exposure.

This kind of Form 4 matters because it updates the market on how a key insider adjusts their stake. Here, the net effect is a higher aggregate position across entities associated with the reporting person as of 11/19/2025, with significant total share counts involved. A practical focus going forward is whether similar open-market purchases continue in subsequent Form 4s and how the balance between direct and indirect holdings evolves over time, since repeated increases would further concentrate ownership and strengthen economic alignment with other holders.

Insider FROST PHILLIP MD ET AL, Frost Gamma Investments Trust
Role CEO & Chairman | 10% Owner
Bought 580,000 shs ($759K)
Type Security Shares Price Value
Purchase Common Stock 36,325 $1.28 $46K
Purchase Common Stock 58,160 $1.285 $75K
Purchase Common Stock 300 $1.29 $387.00
Purchase Common Stock 21,236 $1.295 $28K
Purchase Common Stock 30,082 $1.30 $39K
Purchase Common Stock 12,993 $1.305 $17K
Purchase Common Stock 66,504 $1.31 $87K
Purchase Common Stock 198,904 $1.315 $262K
Purchase Common Stock 155,496 $1.32 $205K
holding Common Stock -- -- --
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 215,002,773 shares (Indirect, See Footnote); Common Stock — 3,568,951 shares (Direct)
Footnotes (1)
  1. The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. These securities are held by Frost Nevada Investments Trust, of which the Reporting Person is the trustee and Frost-Nevada, L.P. is the sole and exclusive beneficiary. The Reporting Person is one of seven limited partners of Frost-Nevada, L.P. and the sole shareholder of Frost-Nevada Corporation, the sole general partner of Frost-Nevada, L.P. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
FROST PHILLIP MD ET AL
(Last) (First) (Middle)
OPKO HEALTH, INC.
4400 BISCAYNE BLVD.
(Street)
MIAMI FL 33137
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
OPKO HEALTH, INC. [ OPK ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director X 10% Owner
X Officer (give title below) Other (specify below)
CEO & Chairman
3. Date of Earliest Transaction (Month/Day/Year)
11/19/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
X Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/19/2025 P 36,325 A $1.28 215,002,773 I See Footnote(1)
Common Stock 11/19/2025 P 58,160 A $1.285 215,060,933 I See Footnote(1)
Common Stock 11/19/2025 P 300 A $1.29 215,061,233 I See Footnote(1)
Common Stock 11/19/2025 P 21,236 A $1.295 215,082,469 I See Footnote(1)
Common Stock 11/19/2025 P 30,082 A $1.3 215,112,551 I See Footnote(1)
Common Stock 11/19/2025 P 12,993 A $1.305 215,125,544 I See Footnote(1)
Common Stock 11/19/2025 P 66,504 A $1.31 215,192,048 I See Footnote(1)
Common Stock 11/19/2025 P 198,904 A $1.315 215,390,952 I See Footnote(1)
Common Stock 11/19/2025 P 155,496 A $1.32 215,546,448 I See Footnote(1)
Common Stock 3,568,951 D
Common Stock 30,127,177 I See Footnote(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
1. Name and Address of Reporting Person*
FROST PHILLIP MD ET AL
(Last) (First) (Middle)
OPKO HEALTH, INC.
4400 BISCAYNE BLVD.
(Street)
MIAMI FL 33137
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
X Director X 10% Owner
X Officer (give title below) Other (specify below)
CEO & Chairman
1. Name and Address of Reporting Person*
Frost Gamma Investments Trust
(Last) (First) (Middle)
OPKO HEALTH, INC.
4400 BISCAYNE BLVD.
(Street)
MIAMI FL 33137
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
Explanation of Responses:
1. The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
2. These securities are held by Frost Nevada Investments Trust, of which the Reporting Person is the trustee and Frost-Nevada, L.P. is the sole and exclusive beneficiary. The Reporting Person is one of seven limited partners of Frost-Nevada, L.P. and the sole shareholder of Frost-Nevada Corporation, the sole general partner of Frost-Nevada, L.P. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
Phillip Frost, M.D., Individually and as Trustee 11/19/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did OPKO Health (OPK) report on this Form 4?

The Form 4 reports that Phillip Frost, M.D., OPKO Health’s CEO, Chairman and 10% owner, made multiple open market purchases of OPKO common stock on 11/19/2025.

How many OPKO Health shares did Phillip Frost acquire and at what prices?

On 11/19/2025, Phillip Frost acquired a total of 580,000 shares of OPKO Health common stock in several trades at prices between $1.28 and $1.32 per share.

What is Phillip Frost’s reported beneficial ownership in OPKO Health after the transactions?

After the reported purchases, Phillip Frost was shown as indirectly beneficially owning 215,546,448 shares through Frost Gamma Investments Trust, plus 3,568,951 shares held directly and 30,127,177 shares held indirectly through Frost Nevada entities.

Does Phillip Frost disclaim any beneficial ownership of these OPKO Health securities?

Yes. The filing states that the reporting person disclaims beneficial ownership of the securities reported through Frost Gamma and Frost Nevada structures, except to the extent of any pecuniary interest.

What roles does Phillip Frost hold at OPKO Health according to this Form 4?

Phillip Frost is identified as a Director, CEO & Chairman, and a 10% Owner of OPKO Health.